Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Western blot [2]
- Immunocytochemistry [1]
- Immunohistochemistry [2]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-13776 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- PDK4 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 200 µL
- Concentration
- 2 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references PDK4 Inhibition Ameliorates Melatonin Therapy by Modulating Cerebral Metabolism and Remyelination in an EAE Demyelinating Mouse Model of Multiple Sclerosis.
miR-32 promotes MYC-driven prostate cancer.
Adropin reduces blood glucose levels in mice by limiting hepatic glucose production.
Ghareghani M, Farhadi Z, Rivest S, Zibara K
Frontiers in immunology 2022;13:862316
Frontiers in immunology 2022;13:862316
miR-32 promotes MYC-driven prostate cancer.
Scaravilli M, Koivukoski S, Gillen A, Bouazza A, Ruusuvuori P, Visakorpi T, Latonen L
Oncogenesis 2022 Mar 1;11(1):11
Oncogenesis 2022 Mar 1;11(1):11
Adropin reduces blood glucose levels in mice by limiting hepatic glucose production.
Thapa D, Xie B, Manning JR, Zhang M, Stoner MW, Huckestein BR, Edmunds LR, Zhang X, Dedousis NL, O'Doherty RM, Jurczak MJ, Scott I
Physiological reports 2019 Apr;7(8):e14043
Physiological reports 2019 Apr;7(8):e14043
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of PDK4 using a PDK4 polyclonal antibody (Product # PA5-13776) in mouse skeletal muscle tissue lysate.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis using a PDK4 polyclonal antibody (Product # PA5-13776) in K562 cell lysates (35 µg per lane).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of HeLa cells using a PDK4 polyclonal antibody (Product # PA5-13776). HeLa cells were fixed with 4% PFA (20 min), permeabilized with Triton X-100 (0.2%, 30 min). Cells were then incubated with a PDK4 polyclonal antibody (Product # PA5-13776) (1:100, 2 hr at room temperature). Primary antibody detected by fluor-conjugated donkey anti-rabbit secondary antibody (green) was used (1:1000, 1hr). Nuclei were counterstained with Hoechst 33342 (blue) (10 µg/mL, 5 min).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of formalin-fixed, paraffin-embedded human Adrenal tissue using a PDK4 polyclonal antibody (Product # PA5-13776), followed by HRP-conjugated secondary antibody and AEC staining.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of formalin-fixed, paraffin-embedded human skeletal muscle tissue using a PDK4 polyclonal antibody (Product # PA5-13776), followed by HRP-conjugated secondary antibody and DAB staining.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 4 PDK4 is a prostate cancer-relevant target of miR-32. A Correlation analysis of PDK4 expression defined by RNA-seq [] and miR-32 expression defined by RT-qPCR in 15 human primary PC samples show an inverse correlation between the expression of these genes. B RNA expression analysis in prostate tissue samples of BPH, primary cancer (PC), and CRPC in the Tampere patient cohort showed decreased PDK4 expression in CRPC compared to PC. C RNA expression analysis in prostate tissue samples of normal, primary cancer, and metastases including both non-castrate and castration-resistant samples in the Taylor et al. [] patient cohort showing decreased PDK4 expression in metastatic compared to PC samples. D RNA expression analysis in prostate tissue samples of primary PC samples in the Taylor et al. [] patient cohort showing relatively decreased PDK4 expression in samples with higher Gleason grades. E Survival proportions of patients with primary PC in the Taylor et al. [] data set between tumors of high and low PDK4 expression show decreased recurrence-free survival for patients with low PDK4-expressing tumors. F Luciferase assay in HeLa cells transfected with control (no-UTR, scramble-3'-UTR) and PDK4-3'UTR luciferase constructs and the indicated pre-miRNAs showing targeting of PDK4-3'-UTR construct targeting by pre-miR-32-3p. G Downregulation of PDK4 expression increases the relative metabolic activity as defined by Alamar Blue assay of 22Rv1 PC cells. H Immunofluorescence analys
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Expression of PDK4. PDK4 levels after administration of melatonin with DADA in brain homogenates (A) mRNA expression levels of PDK4 assessed by real time-PCR. (B, C) Protein expression levels of PDK4 assessed by western blot. beta-actin was used as an internal control for normalization for both real time-PCR and western blot. PDK4 expression levels was normalized to controls. Significance is indicated by **p < 0.01 and ***p < 0.001.